Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009–2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus
Article first published online: 17 NOV 2011
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK
Volume 28, Issue 12, pages 1530–1536, December 2011
How to Cite
Zuccotti, G. V., Pariani, E., Scaramuzza, A., Santoro, L., Giani, E., Macedoni, M., Gazzarri, A., Anselmi, G., Amendola, A. and Zanetti, A. (2011), Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009–2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus. Diabetic Medicine, 28: 1530–1536. doi: 10.1111/j.1464-5491.2011.03449.x
- Issue published online: 17 NOV 2011
- Article first published online: 17 NOV 2011
- Accepted manuscript online: 14 SEP 2011 06:33PM EST
- Accepted 6 September 2011
- H1N1 vaccine;
- influenza vaccine;
- Type 1 diabetes
Diabet. Med. 28, 1530–1536 (2011)
Aims To evaluate the long-lasting immunogenicity and safety of a pandemic vaccine co-administered with a seasonal influenza vaccine in young subjects with Type 1 diabetes.
Methods Eighty patients (mean age: 16.7 ± 5.5 years, disease duration: 10.2 ± 4.7 years) were randomly assigned to receive a single or a double dose (1 month apart) of MF59-adjuvanted influenza A(H1N1) vaccine, simultaneously with a single dose of a virosome-adjuvanted trivalent influenza vaccine for the 2009–2010 season.
Results One month after immunization, the rate of seroconversion to 2009 pandemic A(H1N1) was 92.5% with an overall 100% proportion of vaccinees with protective antibody titres (≥ 1:40). No significant differences were observed between vaccinees who received the one-dose or the two-dose schedule. Seasonal vaccine induced a significant increase of both seroprotection rates and antibody levels. Local adverse events at the injection site of pandemic and seasonal vaccines were reported by 66.3% and 50% of subjects, respectively. Solicited systemic adverse events, mainly mild in intensity, were reported by 26.7% of vaccinees. No subjects had an influenza-like illness during the 6-month follow-up.
Conclusions One injection of 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine is immunogenic and safe in young patients with Type 1 diabetes who are at increased risk of influenza morbidities. Pandemic vaccine can be safely co-administered with seasonal influenza vaccine.